Targeting the tricky PI3K pathway in cancer, MEI gets $75M to push program through registration study
MEI Pharma $MEIP, a small public company in San Diego, has raised $75 million in a private sale of stock to push forward its PI3K …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
